Lilly-话题@MedSci - 梅斯（MedSci）

#Lilly#

9篇内容 | 1088人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2028059, encodeId=09192028059d9, content=<a href='/topic/show?id=a3141089068' target=_blank style='color:#2F92EE;'>#Lilly#</a>, objectTitle=礼来（Lilly）的Olumiant在狼疮、特应性皮炎适应症中遭遇挫折, objectType=article, longId=295103, objectId=2e0c295103eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e0c295103eb, replyNumber=0, likeNumber=76, createdTime=2022-04-08, rootId=0, userName=syscxl, userId=5b27406, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e0c295103eb, moduleTitle=礼来（Lilly）的Olumiant在狼疮、特应性皮炎适应症中遭遇挫折, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=2e0c295103eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2028058, encodeId=88742028058b8, content=<a href='/topic/show?id=a3141089068' target=_blank style='color:#2F92EE;'>#Lilly#</a>, objectTitle=Eli Lilly的Cyramza作为转移性非小细胞肺癌的一线治疗达到了3期临床试验的主要终点, objectType=article, longId=162242, objectId=fef6162242d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fef6162242d9, replyNumber=0, likeNumber=80, createdTime=2020-01-26, rootId=0, userName=syscxl, userId=5b27406, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fef6162242d9, moduleTitle=Eli Lilly的Cyramza作为转移性非小细胞肺癌的一线治疗达到了3期临床试验的主要终点, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=fef6162242d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2028057, encodeId=bbbc202805eb9, content=<a href='/topic/show?id=a3141089068' target=_blank style='color:#2F92EE;'>#Lilly#</a>, objectTitle=FDA批准Lilly的CGRP单抗Emgality用于预防偏头痛, objectType=article, longId=149964, objectId=f791149964f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f791149964f3, replyNumber=0, likeNumber=57, createdTime=2019-01-29, rootId=0, userName=syscxl, userId=5b27406, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f791149964f3, moduleTitle=FDA批准Lilly的CGRP单抗Emgality用于预防偏头痛, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=f791149964f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2028056, encodeId=a43c202805667, content=<a href='/topic/show?id=a3141089068' target=_blank style='color:#2F92EE;'>#Lilly#</a>, objectTitle=Lilly将启动IXORA-R头对头试验：比较IL-17A单抗Taltz和IL-23单抗Tremfya治疗中度至重度斑块型银屑病患者的疗效, objectType=article, longId=148645, objectId=6dae148645a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6dae148645a9, replyNumber=0, likeNumber=68, createdTime=2019-05-31, rootId=0, userName=syscxl, userId=5b27406, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6dae148645a9, moduleTitle=Lilly将启动IXORA-R头对头试验：比较IL-17A单抗Taltz和IL-23单抗Tremfya治疗中度至重度斑块型银屑病患者的疗效, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=6dae148645a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2028054, encodeId=e6c72028054b3, content=<a href='/topic/show?id=a3141089068' target=_blank style='color:#2F92EE;'>#Lilly#</a>, objectTitle=FDA批准Lilly/Incyte的低剂量JAK抑制剂治疗类风湿性关节炎, objectType=article, longId=136407, objectId=f78d13640ef0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f78d13640ef0, replyNumber=0, likeNumber=80, createdTime=2019-03-22, rootId=0, userName=syscxl, userId=5b27406, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f78d13640ef0, moduleTitle=FDA批准Lilly/Incyte的低剂量JAK抑制剂治疗类风湿性关节炎, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=f78d13640ef0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2028055, encodeId=becf2028055e8, content=<a href='/topic/show?id=a3141089068' target=_blank style='color:#2F92EE;'>#Lilly#</a>, objectTitle=Boehringer Ingelheim和Lilly宣布empagliflozin作为1型糖尿病胰岛素的辅助治疗的全新结果, objectType=article, longId=141739, objectId=e257141e399a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e257141e399a, replyNumber=0, likeNumber=97, createdTime=2019-01-02, rootId=0, userName=syscxl, userId=5b27406, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e257141e399a, moduleTitle=Boehringer Ingelheim和Lilly宣布empagliflozin作为1型糖尿病胰岛素的辅助治疗的全新结果, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=e257141e399a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2028053, encodeId=0c4d202805390, content=<a href='/topic/show?id=a3141089068' target=_blank style='color:#2F92EE;'>#Lilly#</a>, objectTitle=BI，Lilly扩展Jardiance在心脏衰竭的应用, objectType=article, longId=131791, objectId=42cb131e9137, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=42cb131e9137, replyNumber=0, likeNumber=67, createdTime=2018-08-26, rootId=0, userName=syscxl, userId=5b27406, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=42cb131e9137, moduleTitle=BI，Lilly扩展Jardiance在心脏衰竭的应用, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=42cb131e9137)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2028052, encodeId=3d5c20280524c, content=<a href='/topic/show?id=a3141089068' target=_blank style='color:#2F92EE;'>#Lilly#</a>, objectTitle=Boehringer和Eli Lilly糖尿病新药empagliflozin三期研究数据公布, objectType=article, longId=20862, objectId=c4442086208, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c4442086208, replyNumber=0, likeNumber=69, createdTime=2013-07-18, rootId=0, userName=syscxl, userId=5b27406, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c4442086208, moduleTitle=Boehringer和Eli Lilly糖尿病新药empagliflozin三期研究数据公布, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=c4442086208)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2028051, encodeId=063c20280510d, content=<a href='/topic/show?id=a3141089068' target=_blank style='color:#2F92EE;'>#Lilly#</a>, objectTitle=礼来（Lilly）公司牛皮癣单抗药物ixekizumab中期临床达到预期目标, objectType=article, longId=5403, objectId=0c8c5403a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c8c5403a3, replyNumber=0, likeNumber=66, createdTime=2013-03-05, rootId=0, userName=syscxl, userId=5b27406, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c8c5403a3, moduleTitle=礼来（Lilly）公司牛皮癣单抗药物ixekizumab中期临床达到预期目标, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=0c8c5403a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Lilly

2020-05-29

syscxl (审核中...)

前往app查看评论内容

#Lilly#

礼来（Lilly）的Olumiant在狼疮、特应性皮炎适应症中遭遇挫折

2022-04-08

syscxl (审核中...)

前往app查看评论内容

#Lilly#

Eli Lilly的Cyramza作为转移性非小细胞肺癌的一线治疗达到了3期临床试验的主要终点

2020-01-26

syscxl (审核中...)

前往app查看评论内容

#Lilly#

FDA批准Lilly的CGRP单抗Emgality用于预防偏头痛

2019-01-29

syscxl (审核中...)

前往app查看评论内容

#Lilly#

Lilly将启动IXORA-R头对头试验：比较IL-17A单抗Taltz和IL-23单抗Tremfya治疗中度至重度斑块型银屑病患者的疗效

2019-05-31

syscxl (审核中...)

前往app查看评论内容

#Lilly#

FDA批准Lilly/Incyte的低剂量JAK抑制剂治疗类风湿性关节炎

2019-03-22

syscxl (审核中...)

前往app查看评论内容

#Lilly#

Boehringer Ingelheim和Lilly宣布empagliflozin作为1型糖尿病胰岛素的辅助治疗的全新结果

2019-01-02

syscxl (审核中...)

前往app查看评论内容

#Lilly#

BI，Lilly扩展Jardiance在心脏衰竭的应用

2018-08-26

syscxl (审核中...)

前往app查看评论内容

#Lilly#

Boehringer和Eli Lilly糖尿病新药empagliflozin三期研究数据公布

2013-07-18

syscxl (审核中...)

前往app查看评论内容

#Lilly#

礼来（Lilly）公司牛皮癣单抗药物ixekizumab中期临床达到预期目标

2013-03-05

科室
- - 订阅+
  - 更多科室
工具
服务